Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Computational Intelligence-Assisted Understanding of Nature-Inspired Superhydrophobic Behavior.

Zhang X, Ding B, Cheng R, Dixon SC, Lu Y.

Adv Sci (Weinh). 2017 Dec 8;5(1):1700520. doi: 10.1002/advs.201700520. eCollection 2018 Jan.

2.

Transforming a Simple Commercial Glue into Highly Robust Superhydrophobic Surfaces via Aerosol-Assisted Chemical Vapor Deposition.

Zhuang A, Liao R, Lu Y, Dixon SC, Jiamprasertboon A, Chen F, Sathasivam S, Parkin IP, Carmalt CJ.

ACS Appl Mater Interfaces. 2017 Dec 6;9(48):42327-42335. doi: 10.1021/acsami.7b13182. Epub 2017 Nov 17.

PMID:
29116744
3.

Lymphadenectomy in Early-Stage Intermediate-/High-Risk Endometrioid Endometrial Cancer: Clinical Characteristics and Outcomes in an Australian Cohort.

Farrell R, Dixon SC, Carter J, Webb PM.

Int J Gynecol Cancer. 2017 Sep;27(7):1379-1386. doi: 10.1097/IGC.0000000000001039.

PMID:
30814240
4.

Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium.

Dixon SC, Nagle CM, Wentzensen N, Trabert B, Beeghly-Fadiel A, Schildkraut JM, Moysich KB, deFazio A; Australian Ovarian Cancer Study Group, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Goodman MT, Modugno F, Ness RB, Edwards RP, Jensen A, Kjær SK, Høgdall E, Berchuck A, Cramer DW, Terry KL, Poole EM, Bandera EV, Paddock LE, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Pearce CL, Wu AH, Pike MC, Webb PM.

Br J Cancer. 2017 Apr 25;116(9):1223-1228. doi: 10.1038/bjc.2017.68. Epub 2017 Mar 28.

5.

Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study.

Dixon SC, Nagle CM, Thrift AP, Pharoah PD, Pearce CL, Zheng W, Painter JN; AOCS Group & Australian Cancer Study (Ovarian Cancer), Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Rudolph A, Moysich KB, Odunsi K, Goodman MT, Wilkens LR, Thompson PJ, Shvetsov YB, Dörk T, Park-Simon TW, Hillemanns P, Bogdanova N, Butzow R, Nevanlinna H, Pelttari LM, Leminen A, Modugno F, Ness RB, Edwards RP, Kelley JL, Heitz F, Karlan BY, Kjær SK, Høgdall E, Jensen A, Goode EL, Fridley BL, Cunningham JM, Winham SJ, Giles GG, Bruinsma F, Milne RL, Southey MC, Hildebrandt MA, Wu X, Lu KH, Liang D, Levine DA, Bisogna M, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Bandera EV, Olson SH, Salvesen HB, Thomsen LC, Kopperud RK, Bjorge L, Kiemeney LA, Massuger LF, Pejovic T, Cook LS, Le ND, Swenerton KD, Brooks-Wilson A, Kelemen LE, Lubiński J, Huzarski T, Gronwald J, Menkiszak J, Wentzensen N, Brinton L, Yang H, Lissowska J, Høgdall CK, Lundvall L, Song H, Tyrer JP, Campbell I, Eccles D, Paul J, Glasspool R, Siddiqui N, Whittemore AS, Sieh W, McGuire V, Rothstein JH, Narod SA, Phelan C, Risch HA, McLaughlin JR, Anton-Culver H, Ziogas A, Menon U, Gayther SA, Ramus SJ, Gentry-Maharaj A, Wu AH, Pike MC, Tseng CC, Kupryjanczyk J, Dansonka-Mieszkowska A, Budzilowska A, Spiewankiewicz B, Webb PM; Ovarian Cancer Association Consortium.

Int J Epidemiol. 2016 Jun;45(3):884-95. doi: 10.1093/ije/dyw158. Epub 2016 Jul 10.

6.

Assessing the genetic architecture of epithelial ovarian cancer histological subtypes.

Cuellar-Partida G, Lu Y, Dixon SC; Australian Ovarian Cancer Study, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Doherty JA, Rossing MA, Chang-Claude J, Rudolph A, Wang-Gohrke S, Goodman MT, Bogdanova N, Dörk T, Dürst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Leminen A, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Høgdall E, Høgdall C, Jensen A, Giles GG, Bruinsma F, Kjaer SK, Hildebrandt MA, Liang D, Lu KH, Wu X, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Missmer S, Bjorge L, Salvesen HB, Kopperud RK, Bischof K, Aben KK, Kiemeney LA, Massuger LF, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Blake Gilks C, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Song H, Tyrer JP, Wentzensen N, Brinton L, Trabert B, Lissowska J, McLaughlin JR, Narod SA, Phelan C, Anton-Culver H, Ziogas A, Eccles D, Campbell I, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Dansonka-Mieszkowska A, Kupryjanczyk J, Timorek A, Szafron L, Cunningham JM, Fridley BL, Winham SJ, Bandera EV, Poole EM, Morgan TK, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PD, Webb PM, Chenevix-Trench G, Risch HA, MacGregor S.

Hum Genet. 2016 Jul;135(7):741-56. doi: 10.1007/s00439-016-1663-9. Epub 2016 Apr 13.

7.

Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium.

Nagle CM, Dixon SC, Jensen A, Kjaer SK, Modugno F, deFazio A, Fereday S, Hung J, Johnatty SE; Australian Ovarian Cancer Study Group, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Van Nieuwenhuysen E, Lambrechts S, Risch HA, Rossing MA, Doherty JA, Wicklund KG, Chang-Claude J, Goodman MT, Ness RB, Moysich K, Heitz F, du Bois A, Harter P, Schwaab I, Matsuo K, Hosono S, Goode EL, Vierkant RA, Larson MC, Fridley BL, Høgdall C, Schildkraut JM, Weber RP, Cramer DW, Terry KL, Bandera EV, Paddock L, Rodriguez-Rodriguez L, Wentzensen N, Yang HP, Brinton LA, Lissowska J, Høgdall E, Lundvall L, Whittemore A, McGuire V, Sieh W, Rothstein J, Sutphen R, Anton-Culver H, Ziogas A, Pearce CL, Wu AH, Webb PM; Ovarian Cancer Association Consortium.

Br J Cancer. 2015 Sep 1;113(5):817-26. doi: 10.1038/bjc.2015.245. Epub 2015 Jul 7.

8.

'As many options as there are, there are just not enough for me': contraceptive use and barriers to access among Australian women.

Dixon SC, Herbert DL, Loxton D, Lucke JC.

Eur J Contracept Reprod Health Care. 2014 Oct;19(5):340-51. doi: 10.3109/13625187.2014.919380. Epub 2014 Jun 5.

PMID:
24901891
9.

Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival.

Dixon SC, Ibiebele TI, Protani MM, Beesley J, deFazio A, Crandon AJ, Gard GB, Rome RM, Webb PM, Nagle CM; Australian Ovarian Cancer Study Group.

Gynecol Oncol. 2014 Mar;132(3):566-72. doi: 10.1016/j.ygyno.2013.12.025. Epub 2013 Dec 22.

PMID:
24368279
10.

Apoptosis: a novel therapeutic tool?

Dixon SC, Arah IN.

Expert Opin Investig Drugs. 1998 Jun;7(6):889-904.

PMID:
15992005
11.

The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.

Cude KJ, Montgomery JS, Price DK, Dixon SC, Kincaid RL, Kovacs KF, Venzon DJ, Liewehr DJ, Johnson ME, Reed E, Figg WD.

Urol Int. 2002;68(1):16-23.

PMID:
11803263
12.

Resistance to growth inhibitory and apoptotic effects of phorbol ester and UCN-01 in aggressive cancer cell lines.

Blagosklonny MV, Dixon SC, Robey R, Figg WD.

Int J Oncol. 2001 Apr;18(4):697-704.

PMID:
11251163
13.

The control of prostate-specific antigen expression and gene regulation by pharmacological agents.

Dixon SC, Knopf KB, Figg WD.

Pharmacol Rev. 2001 Mar;53(1):73-91. Review.

PMID:
11171939
14.
15.

Endostatin inhibits microvessel formation in the ex vivo rat aortic ring angiogenesis assay.

Kruger EA, Duray PH, Tsokos MG, Venzon DJ, Libutti SK, Dixon SC, Rudek MA, Pluda J, Allegra C, Figg WD.

Biochem Biophys Res Commun. 2000 Feb 5;268(1):183-91.

PMID:
10652234
16.

UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.

Kruger EA, Blagosklonny MV, Dixon SC, Figg WD.

Invasion Metastasis. 1998-1999;18(4):209-18.

PMID:
10640907
17.

Carboxyamido-triazole inhibits angiogenesis by blocking the calcium-mediated nitric-oxide synthase-vascular endothelial growth factor pathway.

Bauer KS, Cude KJ, Dixon SC, Kruger EA, Figg WD.

J Pharmacol Exp Ther. 2000 Jan;292(1):31-7.

PMID:
10604929
18.

Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.

Arah IN, Dixon SC, Horti J, Figg WD.

Neoplasma. 1999;46(2):117-23.

PMID:
10466436
19.

Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor.

Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD.

Clin Cancer Res. 1999 Jul;5(7):1738-44.

20.

The androgen receptor: genetic considerations in the development and treatment of prostate cancer.

Cude KJ, Dixon SC, Guo Y, Lisella J, Figg WD.

J Mol Med (Berl). 1999 May;77(5):419-26. Review.

PMID:
10426191
21.

Thalidomide up-regulates prostate-specific antigen secretion from LNCaP cells.

Dixon SC, Kruger EA, Bauer KS, Figg WD.

Cancer Chemother Pharmacol. 1999;43 Suppl:S78-84.

PMID:
10357564
22.

Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.

Horti J, Dixon SC, Logothetis CJ, Guo Y, Reed E, Figg WD.

Br J Cancer. 1999 Mar;79(9-10):1588-93.

23.

Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent.

Bauer KS, Dixon SC, Figg WD.

Biochem Pharmacol. 1998 Jun 1;55(11):1827-34.

PMID:
9714301
24.

Methods for extracting and amplifying genomic DNA isolated from frozen serum.

Dixon SC, Horti J, Guo Y, Reed E, Figg WD.

Nat Biotechnol. 1998 Jan;16(1):91-4. No abstract available.

PMID:
9447601
25.

In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.

Dixon SC, Zalles A, Giordano C, Lush RM, Venzon D, Reed E, Figg WD.

Cancer Lett. 1997 Feb 26;113(1-2):111-6.

PMID:
9065809
26.

Apoptosis: its role in the development of malignancies and its potential as a novel therapeutic target.

Dixon SC, Soriano BJ, Lush RM, Borner MM, Figg WD.

Ann Pharmacother. 1997 Jan;31(1):76-82. Review.

PMID:
8997471
27.

Bivariate flow cytometry of farm animal chromosomes: a potential tool for gene mapping.

Dixon SC, Miller NG, Carter NP, Tucker EM.

Anim Genet. 1992;23(3):203-10.

PMID:
1503256
28.

A chromosome 1-specific DNA library from the domestic pig (Sus scrofa domestica).

Miller JR, Dixon SC, Miller NG, Tucker EM, Hindkjaer J, Thomsen PD.

Cytogenet Cell Genet. 1992;61(2):128-31.

PMID:
1395721
29.

Synteny mapping of the bovine IGHG2, CRC and IGF1 genes.

Miller JR, Thomsen PD, Dixon SC, Tucker EM, Konfortov BA, Harbitz I.

Anim Genet. 1992;23(1):51-8.

PMID:
1349204
30.

Cloning and characterization of molecular isoforms of the catalytic subunit of calcineurin using nonisotopic methods.

Kincaid RL, Giri PR, Higuchi S, Tamura J, Dixon SC, Marietta CA, Amorese DA, Martin BM.

J Biol Chem. 1990 Jul 5;265(19):11312-9.

31.

Two new sheep haemoglobins, one of which is replaced by haemoglobin C in anaemia.

Kilgour L, Dixon SC, Tucker EM.

Anim Genet. 1990;21(2):115-21.

PMID:
2386310
32.

Restricted replication of human adenovirus type 5 in mouse cell lines.

Blair GE, Dixon SC, Griffiths SA, Zajdel ME.

Virus Res. 1989 Dec;14(4):339-46.

PMID:
2560294
34.

The use of monoclonal antibodies to study the proteins specified by the transforming region of human adenoviruses.

Blair Zajdel ME, Barker MD, Dixon SC, Blair GE.

Biochem J. 1985 Feb 1;225(3):649-55.

35.

Supplemental Content

Loading ...
Support Center